Krystal Biotech (NASDAQ:KRYS) Issues Quarterly Earnings Results

Krystal Biotech (NASDAQ:KRYS) released its quarterly earnings results on Monday. The company reported $1.52 EPS for the quarter, topping the consensus estimate of $1.29 by $0.23, Zacks reports. The company had revenue of $91.10 million for the quarter, compared to analyst estimates of $91.35 million. Krystal Biotech had a return on equity of 11.41% and a net margin of 30.69%. The firm’s revenue was up 116.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.30 earnings per share.

Krystal Biotech Price Performance

Krystal Biotech stock opened at $186.89 on Tuesday. Krystal Biotech has a 12 month low of $125.85 and a 12 month high of $219.34. The business has a 50 day simple moving average of $158.24 and a 200-day simple moving average of $175.31. The stock has a market capitalization of $5.38 billion, a PE ratio of 62.51 and a beta of 0.84.

Analyst Upgrades and Downgrades

Several research analysts have commented on KRYS shares. HC Wainwright reaffirmed a “buy” rating and set a $221.00 price target on shares of Krystal Biotech in a research report on Wednesday, February 19th. Citigroup lifted their price target on Krystal Biotech from $206.00 to $215.00 and gave the stock a “neutral” rating in a research report on Thursday, February 20th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $215.00 price target on shares of Krystal Biotech in a research report on Thursday, February 20th. Finally, Chardan Capital boosted their target price on Krystal Biotech from $212.00 to $218.00 and gave the company a “buy” rating in a report on Thursday, February 20th. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Krystal Biotech has a consensus rating of “Buy” and a consensus target price of $210.00.

Insider Transactions at Krystal Biotech

In related news, insider Suma Krishnan sold 25,000 shares of the company’s stock in a transaction on Friday, December 13th. The stock was sold at an average price of $164.78, for a total transaction of $4,119,500.00. Following the transaction, the insider now owns 1,475,882 shares of the company’s stock, valued at $243,195,835.96. This represents a 1.67 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Company insiders own 14.10% of the company’s stock.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).